La vendita allo scoperto per Ontrak dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Ontrak. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Ontrak (NASDAQ:OTRK) Azioni, Report sulle vendite allo scoperto

Ontrak

Ontrak Inc is an artificial intelligence (AI)-powered and technology-enabled behavioral healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. The Company's technology-enabled platform utilizes claim-based analytics and predictive modeling to provide analytic insights throughout the delivery of our personalized care program. The company's integrated, technology-enabled OntrakTM solutions, a component of the PRE platform, are designed to treat members with behavioral conditions that cause chronic medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure.

Ontrak Inc

Democratic Governor <a href="https://www.benzinga.com/topic/andy-beshear">Andy Beshear </a>announced on Thursday that Kentucky's medical marijuana program is right on schedule and ready to meet its Dec. 1 launch date.
"Beginning December 1, the authorized practitioners will be able to begin issuing valid written certifications to Kentucky patients," Beshear <a href="https://www.youtube.com/results?search_query=gov+andy+beshear+live+today">said </a>in his Thursday Team Kentucky address. "So on December 1, not only can you go online and find where these practitioners are, but you can go ahead and go see them and have your written certification issued to them."
Since July, 154 health professionals have been authorized as medical cannabis practitioners. To ensure seamless access for patients, Beshear's administration has launched the Kentucky Medical Cannabis Practitioner Directory, an online tool that will also go live on December 1.
"This tool will ensure Kentuckians can find the care they need close to home," Beshear said. "But ultimately medical cannabis is about health care the purpose of this program is to help Kentuckians who are suffering."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42127698/long-term-study-reveals-cannabis-may-slow-cognitive-decline-everything-you-need-to-know">Long-Term Study Reveals Cannabis May Slow Cognitive Decline: Everything You Need To Know</a>
The spotlight now shifts to dispensary licensing, with two lotteries planned to determine selectees. The first lottery, covering nine of the state's 11 medical cannabis regions, will take place the Monday before Thanksgiving in Louisville. The final two regions will have their licensees drawn on Dec. 16.
The Kentucky Office of Medical Cannabis has already issued 29 licenses for cultivators, processors and safety compliance facilities, laying the groundwork for a robust supply chain, <a href="https://westkentuckystar.com/News/State/Governor-Beshear-offers-update-on-medical-cannibis">noted</a> the West Kentucky Star.
Meanwhile, local support for the program continues to grow. During the November elections, over 100 Kentucky cities and counties <a href="https://www.benzinga.com/general/health-care/24/11/41843261/kentucky-gov-beshear-the-jury-is-no-longer-out-kentuckians-want-medical-cannabis">approved ordinances</a> allowing medical marijuana businesses to operate in their jurisdictions.
"The jury is no longer out," Beshear said at the time, noting the bipartisan support among voters. "Kentuckians want their families, friends, and neighbors with serious medical conditions to have access to safe and effective treatment. We're keeping our promise to make that a reality."
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42127911/gop-led-group-calls-for-legal-cannabis-in-indiana-tell-your-legislator-its-time">GOP-Led Group Calls For Legal Cannabis In Indiana: &#8216;Tell Your Legislator It&#8217;s Time&#8217;</a></li>
</ul>
Photo: TeamKentucky.gov

Cannabis

Government

News

Health Care

Legal

Kentucky Gov. Beshear: 'Go Online And Find' Your Medical Marijuana Practitioner On Dec. 1

Lake Street analyst Jacob Stephan maintains Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) with a Buy and raises the price target from $8 to $13.

Price Target

Analyst Ratings

PRTH

Lake Street Maintains Buy on Priority Tech Holdings, Raises Price Target to $13

Barclays analyst Adam Seiden maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Overweight and raises the price target from $400 to $475.

Barclays Maintains Overweight on Deere, Raises Price Target to $475

GLAC

W Straits Limited and Global Lights Acquisition Corp. Sign Non-Binding Letter of Intent For Business Combination; W Straights' Shareholders Exchanging Shares For Equity In Combined Public Company

Barclays analyst Andrew Mok maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Overweight and lowers the price target from $76 to $43.

ACHC

Barclays Maintains Overweight on Acadia Healthcare Co, Lowers Price Target to $43

Loop Capital analyst Chris Dankert maintains Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) with a Buy and lowers the price target from $130 to $115.

ATKR

Loop Capital Maintains Buy on Atkore, Lowers Price Target to $115

UPXI

Upexi Receives Nasdaq Non Compliance Notice

~ Mission critical industrial facility meets Level 4 security requirements with advanced bomb detection capabilities and chemical sniffing K9s ~

Easterly Government Properties Acquires 100,000 Leased Square Foot Facility; Amount Not Disclosed

TZUP

Thumzup Says Its Ad-Tech Platform Has Now Attracted Over 500 Advertisers

Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Alarum Technologies will report an earnings per share (EPS) of $0.04.
Alarum Technologies bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.10, leading to a 8.56% drop in the share price the following trading session.
Here's a look at Alarum Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.31</td>
<td>0.28</td>
<td>0.25</td>
<td>0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.41</td>
<td>0.23</td>
<td>0.30</td>
<td>0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>7.000000000000001%</td>
<td>-11.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732284195_0.png" alt="eps graph" />
<h3>Market Performance of Alarum Technologies's Stock</h3>
Shares of Alarum Technologies were trading at $13.29 as of November 19. Over the last 52-week period, shares are up 143.85%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Opinions on Alarum Technologies</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alarum Technologies.
Analysts have given Alarum Technologies a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $28.0, indicating a potential 110.68% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Duos Technologies Group, Silvaco Group and Telos, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Duos Technologies Group received a Buy consensus from analysts, with an average 1-year price target of $8.0, implying a potential 39.8% downside.</li>
<li>As per analysts' assessments, Silvaco Group is favoring an Buy trajectory, with an average 1-year price target of $20.71, suggesting a potential 55.83% upside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Telos, with an average 1-year price target of $4.75, indicating a potential 64.26% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Duos Technologies Group, Silvaco Group and Telos, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alarum Technologies</td>
<td>Buy</td>
<td>27.19%</td>
<td>$6.83M</td>
<td>-1.87%</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>Buy</td>
<td>111.57%</td>
<td>$919.10K</td>
<td>-52.24%</td>
</tr>
<tr>
<td>Silvaco Group</td>
<td>Buy</td>
<td>-26.58%</td>
<td>$8.19M</td>
<td>-6.53%</td>
</tr>
<tr>
<td>Telos</td>
<td>Buy</td>
<td>-34.28%</td>
<td>$3.14M</td>
<td>-20.14%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Alarum Technologies ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit and Return on Equity.
<h3>Discovering Alarum Technologies: A Closer Look</h3>
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
<h3>Breaking Down Alarum Technologies's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Alarum Technologies displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 27.19%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Alarum Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.95% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Alarum Technologies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.87%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.22%, the company showcases effective utilization of assets.
Debt Management: Alarum Technologies's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ALAR/earnings">To track all earnings releases for Alarum Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ALAR

A Glimpse of Alarum Technologies's Earnings Potential

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is a Bitcoin play and he prefers to <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">actually own </a>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
MicroStrategy announced it completed its previously announced offering of its 0% convertible senior notes due 2029. MicroStrategy said the aggregate principal amount of the notes sold in the offering was $3 billion, which includes $400 million aggregate principal amount of notes issued pursuant to an option to purchase.
When asked about Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>), he said, &#8220;Until I saw that Mark Bertolini is the CEO, I didn't really have much in store for this. But Bertolini's a winner and a hitter.&#8221;
On Nov. 7, Oscar Health reported a quarterly loss of 22 cents per share which missed the analyst consensus estimate of a loss of 19 cents per share. The company reported quarterly sales of $2.42 billion which beat the analyst consensus estimate of $2.34 billion.
CNH Industrial N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) is a &#8220;second-rater,&#8221; Cramer said. &#8220;I want to go with best of breed, and best of breed is John Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>).&#8221;
On Nov. 7, CNH Industrial reported worse-than-expected third-quarter EPS results and also lowered FY24 adjusted EPS outlook.
&#8220;The former, BGS, is a total loser and has been a loser for many, many years,&#8221; Cramer said when asked about B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>).
On Nov. 5, B&amp;G Foods reported worse-than-expected third-quarter financial results and issued FY24 net sales guidance below estimates.
When asked about Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), he said, &#8220;It's moth to flame, but I don't know how close the moth is to the flame.&#8221;
On Nov. 19, Goldman Sachs analyst Noah Poponak maintained Rocket Lab with a Neutral and raised the price target from $5 to $12.
Price Action:
<ul>
<li>Oscar Health shares fell 4.1% to settle at $16.31 on Thursday.</li>
<li>CNH Industrial shares gained 4.6% to close at $11.92.</li>
<li>Rocket Lab shares gained 11.1% to close at $22.41.</li>
<li>MicroStrategy shares fell 16.2% to settle at $397.28 during the session.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42122978/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

$BTC

MSTR

OSCR

RKLB

Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin

BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is preparing to release its quarterly earnings on Monday, 2024-11-25. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect BioLine Rx to report an earnings per share (EPS) of $-0.10.
Anticipation surrounds BioLine Rx's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.14, leading to a 8.88% increase in the share price on the subsequent day.
Here's a look at BioLine Rx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.29</td>
<td>-0.22</td>
<td>-0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>-0.01</td>
<td>-0.15</td>
<td>-0.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-4.0%</td>
<td>8.0%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732284187_0.png" alt="eps graph" />
<h3>BioLine Rx Share Price Analysis</h3>
Shares of BioLine Rx were trading at $0.32325 as of November 21. Over the last 52-week period, shares are down 77.86%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BLRX/earnings">To track all earnings releases for BioLine Rx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLRX

Earnings Preview For BioLine Rx

StealthGas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GASS#NASDAQ">GASS</a>) is preparing to release its quarterly earnings on Monday, 2024-11-25. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect StealthGas to report an earnings per share (EPS) of $0.33.
Anticipation surrounds StealthGas's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.22, which was followed by a 1.61% drop in the share price the next day.
Here's a look at StealthGas's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.53</td>
<td>0.24</td>
<td>0.30</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.75</td>
<td>0.53</td>
<td>0.29</td>
<td>0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732284179_0.png" alt="eps graph" />
<h3>Tracking StealthGas's Stock Performance</h3>
Shares of StealthGas were trading at $6.005 as of November 21. Over the last 52-week period, shares are down 11.17%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/GASS/earnings">To track all earnings releases for StealthGas visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GASS

Preview: StealthGas's Earnings

Barclays analyst Manav Patnaik maintains Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) with a Underweight and raises the price target from $10 to $13.

VSTS

Barclays Maintains Underweight on Vestis, Raises Price Target to $13

Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) has secured a $2.38 billion contract to build 15 additional KC-46A Pegasus tankers under the Lot 11 contract with the <a target="_blank" href="https://boeing.mediaroom.com/news-releases-statements?item=131508" rel="noreferrer noopener">U.S. Air Force</a>.
This latest award brings Boeing&#8217;s global contract to 168 KC-46A refuelers, a multi-mission aerial tanker designed to support advanced joint force capabilities.
The KC-46A has proven its operational value, having flown over 100,000 hours and offloading more than 200 million pounds of fuel worldwide.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/24/11/42088437/qualcomm-targets-900-billion-market-by-2030-big-bets-on-iot-and-automotive" rel="noreferrer noopener">Qualcomm Targets $900 Billion Market by 2030: Big Bets on IoT and Automotive</a>
It made its first full-scale deployment in October after being approved for global combat operations in 2022.
This contract builds on the July agreement, which focused on upgrading the KC-46A&#8217;s mission readiness and operational performance. Enhancements include advanced communication systems, improved data connectivity, and situational awareness, further strengthening survivability in contested environments. These upgrades complement the 2023 Block 1 improvements.
Since 2019, Boeing has delivered 89 Pegasus tankers to the U.S. Air Force and four to Japan&#8217;s Air Self-Defense Force. The KC-46A program continues to expand its reach, solidifying its role as a critical asset for U.S. and allied forces.
Boeing reported a 1% revenue decline to $17.85 billion in the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41486950/boeing-q3-earnings-revenue-and-profit-decline-cultural-challenges-ceo-ortberg-vows-transformation" rel="noreferrer noopener">third quarter of 2024</a>, missing the analyst consensus of $17.93 billion. The adjusted operating loss of $5.99 billion, compared to $1.09 billion a year ago.&nbsp;
Last week, Boeing plans to fire <a target="_blank" href="https://www.benzinga.com/news/global/24/11/42052735/boeing-to-lay-off-over-2500-workers-in-the-us-amid-global-workforce-reduction" rel="noreferrer noopener">over 2,500 employees</a> in Washington, Oregon, South Carolina, and Missouri. This reduction is part of a larger effort to cut 17,000 jobs, representing 10% of the company&#8217;s global workforce.
In October, Boeing announced plans to raise <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41606547/boeing-eyes-20-7-billion-windfall-as-stock-offering-expands-details" rel="noreferrer noopener">$21 billion by</a> selling 112.5 million shares at $143.00 each and $5 billion in depositary shares.
Price Action: BA stock is down 0.08% at $143.30 premarket at the last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42092265/stmicroelectronics-targets-18-billion-revenue-eyes-22-24-margins-by-2028" target="_blank" rel="noreferrer noopener">STMicroelectronics Targets $20 Billion Revenue By 2030, Unveils 2027 Goals</a></li>
</ul>
Image via Shutterstock

Contracts

Boeing Secures $2.38 Billion US Air Force Deal for Advanced KC-46A Tankers

The U.S. economy could face a high-stakes, casino-like scenario in 2025, with risks swinging between a potential boom fueled by tax cuts and deregulation and a possible stagflationary bust triggered by policy <a href="https://www.benzinga.com/topic/donald-trump">uncertainty and trade restrictions. </a>
This is the core message from JPMorgan&#8217;s chief economist, Michael Feroli, who laid out a sharply divided economic outlook shaped by the red sweep in the 2024 elections and the early policy indications from the incoming Donald Trump administration.
<h3 class="wp-block-heading">Dueling Narratives For 2025: Economic Boom Or Stagflation</h3>
In a note shared with clients earlier this week, Feroli presented competing narratives about the direction of the U.S. economy in 2025.
&#8220;One path sees tax cuts and deregulation unleashing animal spirits, thereby boosting productivity growth and GDP,&#8221; the economist wrote. 
&#8220;The other path foresees policy uncertainty hindering growth, while trade and immigration restrictions impart a stagflationary bias,&#8221; he added.
Striking a balance between two extremes, JPMorgan projects a modest slowdown in growth to 2% in 2025, accompanied by a slight uptick in unemployment to 4.5%.
Feroli highlights that the U.S. Federal Reserve&#8217;s dual mandate of maximum employment and stable inflation faces a complex road ahead.
While inflation risks have moderated compared to two years ago, core PCE (the Fed&#8217;s preferred inflation gauge) remains stubbornly high, hovering in the upper 2% range. Simultaneously, the labor market is slowing but hasn&#8217;t bottomed in a way that assures confidence in avoiding further unemployment increases.
&#8220;Next year's outlook is cloudier than normal,&#8221; the investment bank wrote.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42136536/ark-invests-cathie-wood-says-team-trump-would-give-regulatory-clarity-for-bitcoin-and-other-digital-assets-which-they-may-put-in-the-treasurys-strategic-reserve">Ark Invest&#8217;s Cathie Wood Says Team Trump Would Give &#8216;Regulatory Clarity&#8217; For Bitcoin And Other Digital Assets: &#8216;&#8230;Which They May Put In The Treasury&#8217;s Strategic Reserve&#8217;</a>
<h2 class="wp-block-heading">Policy and Tariff Risks on the Horizon</h2>
<h3 class="wp-block-heading">Immigration and Labor Supply</h3>
Immigration policy is expected to take center stage in 2025 under the Trump administration. 
A reduction in net immigration could significantly dampen labor supply growth, employment gains, and overall GDP expansion.
JPMorgan projects that immigration restrictions will tighten labor markets, potentially curbing economic growth over the long term.
Yet, they &#8220;don't anticipate immigration policy will have first-order effects on inflation.&#8221;
<h3 class="wp-block-heading">Tariffs On China And Inflation Effects</h3>
On trade policy, JPMorgan assumes a 60% across-the-board tariff on Chinese imports will likely be implemented in 2025. 
Tariffs on imports from other countries are expected to remain more limited in scope, though their potential introduction could further disrupt supply chains.
Currently, U.S. tariffs on Chinese goods stand at 11%. A steep increase to 60% would represent a dramatic escalation and could significantly strain the U.S.-China trade relationship. 
While the broader economic impact is still uncertain, Feroli warns of inflationary pressures arising from such protectionist measures.
&#8220;Based on the volume of trade, the U.S. would be levying $215bn in taxes on Chinese imports and China would be levying just over $70bn in taxes on US exports,&#8221; he stated.
JPMorgan anticipates further progress toward the Fed&#8217;s 2% inflation target in 2025. 
However, policies proposed by President-elect Trump, particularly higher tariffs on China, pose a risk of modestly higher inflation. The most significant impact is expected midyear, as increased tariffs could temporarily lift prices. 
As a result, JPMorgan forecasts core PCE inflation to run at 2.3% by the end of 2025, before gradually aligning with the Fed&#8217;s 2% target in 2026.
<h3 class="wp-block-heading">The Fiscal Deficit: A Growing Challenge</h3>
Fiscal policy is also under scrutiny, as the U.S. budget deficit is projected to expand significantly in the years ahead. 
The Trump administration and a Republican-controlled Congress are expected to extend the 2017 Tax Cuts and Jobs Act (TCJA), whose personal income tax provisions are set to expire at the end of 2025.
&#8220;We expect essentially all the current tax code will be extended, which we project will mean a federal fiscal deficit of around 7% of GDP in 2026, at a time when we are at full employment and not directly involved in a war. The vagaries of the business cycle and geopolitics both skew risks toward a wider deficit,&#8221; Feroli said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42130782/amazon-at-risk-of-major-fine-as-eu-investigates-alleged-preference-for-in-house-products-under-digital-markets-act-report">Amazon At Risk Of Major Fine As EU Investigates Alleged Preference For In-House Products Under Digital Markets Act: Report</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Econ #s

Economics

2025 US Economy Outlook 'Cloudier Than Normal,' JPMorgan Says: Boom, Bust Scenarios

Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is set to give its latest quarterly earnings report on Monday, 2024-11-25. Here's what investors need to know before the announcement.
Analysts estimate that Hesai Gr will report an earnings per share (EPS) of $-0.02. 
The market awaits Hesai Gr's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 7.95% drop in the share price the next day.
Here's a look at Hesai Gr's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.08</td>
<td>-0.11</td>
<td>-0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.08</td>
<td>-0.11</td>
<td>-0.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-14.000000000000002%</td>
<td>-4.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732284151_0.png" alt="eps graph" />
<h3>Tracking Hesai Gr's Stock Performance</h3>
Shares of Hesai Gr were trading at $4.61 as of November 21. Over the last 52-week period, shares are down 56.63%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HSAI/earnings">To track all earnings releases for Hesai Gr visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HSAI

Insights Ahead: Hesai Gr's Quarterly Earnings

Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) is set to give its latest quarterly earnings report on Monday, 2024-11-25. Here's what investors need to know before the announcement.
Analysts estimate that Leslies will report an earnings per share (EPS) of $0.11. 
Anticipation surrounds Leslies's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.08, which was followed by a 14.49% increase in the share price the next day.
Here's a look at Leslies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.42</td>
<td>-0.18</td>
<td>-0.21</td>
<td>0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.34</td>
<td>-0.17</td>
<td>-0.20</td>
<td>0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>14.000000000000002%</td>
<td>11.0%</td>
<td>2.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732284143_0.png" alt="eps graph" />
<h3>Market Performance of Leslies's Stock</h3>
Shares of Leslies were trading at $2.87 as of November 20. Over the last 52-week period, shares are down 49.74%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/LESL/earnings">To track all earnings releases for Leslies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LESL

A Look at Leslies's Upcoming Earnings Report

Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is set to give its latest quarterly earnings report on Monday, 2024-11-25. Here's what investors need to know before the announcement.
Analysts estimate that Semtech will report an earnings per share (EPS) of $0.23. 
Semtech bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 11.19% increase in the share price on the following day.
Here's a look at Semtech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.11</td>
<td>-0.03</td>
<td>-0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.11</td>
<td>0.06</td>
<td>-0.06</td>
<td>0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>11.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>16.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732284135_0.png" alt="eps graph" />
<h3>Semtech Share Price Analysis</h3>
Shares of Semtech were trading at $50.9 as of November 21. Over the last 52-week period, shares are up 210.74%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SMTC/earnings">To track all earnings releases for Semtech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SMTC

A Look at Semtech's Upcoming Earnings Report

Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Agora will report an earnings per share (EPS) of $-0.04.
Agora bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 6.84% drop in the share price the following trading session.
Here's a look at Agora's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.070</td>
<td>-0.09</td>
<td>-0.09</td>
<td>-0.10</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.064</td>
<td>-0.05</td>
<td>0.01</td>
<td>-0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>-11.0%</td>
<td>19.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732284125_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Agora were trading at $4.56 as of November 21. Over the last 52-week period, shares are up 67.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/API/earnings">To track all earnings releases for Agora visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Agora

Ontrak, Inc. (OTRK) Q2 2024 Earnings Call Transcript

Ontrak to conduct 1-for-15 reverse stock split

Ontrak ( ($OTRK) ) has issued an update. Ontrak, Inc. has announced a 1-for-15 reverse stock split, slated to be effective at the start of trading ...

Ontrak Implements Reverse Split to Satisfy Nasdaq Requirements

These are the upcoming stock splits for the week of September 23 to September 27, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a...

Upcoming Stock Splits This Week (September 23 to September 27) – Stay Invested

Ontrak Q3 Earnings Preview

Here are the major earnings after the close today

Ontrak Non-GAAP EPS of -$1.38, revenue of $2.6M in-line

Reports Q3 revenue $2.569M vs $3.715M last year. Brandon LaVerne, Ontrak (OTRK) Health's Chief Executive Officer, stated, "I am thrilled that we ha...

Ontrak reports Q3 EPS ($1.38) vs ($24.15) last year

Ontrak, Inc. (OTRK) Q3 2024 Earnings Call Transcript

Ontrak, Inc. ( ($OTRK) ) has released its Q3 earnings. Here is a breakdown of the information Ontrak, Inc. presented to its investors. Ontrak, Inc....

Ontrak, Inc. Reports Q3 Earnings and Strategic Initiatives

ADAP

AEMD

AGRO

AOIFF

AYTU

BDORY

BNGO

BOXL

BRFS

CAPR

CSCO

DADA

DGII

DRRX

ECOR

EVTL

GLAD

GOEV

GRYP

HROW

KLIC

MPLN

NLCP

OMER

OTRK

OTRKP

PVCT

RSLS

SMSI

SONO

SPRU

TLPH

TRAW

TTEK

VXRT

Press Releases

Ontrak Health and MosaicVoice Partner to Revolutionize Healthcare with AI-Powered Voice Technology

Ontrak Health Launches Innovative Solution to Improve Quality Measures and Boost Performance Scores

Ontrak Health to Present at National Healthcare Industry Events

Ontrak Health Demonstrates Significant Improvement in Members' Quality of Life from ReQoL Mental Health Assessment

Ontrak, Inc. Announces Reverse Stock Split

"Peraso Inc. (NASDAQ: PSRO) Pioneers mmWave Technology: The Next-Generation Wireless Communications" see bonus stocks inside…..

Ontrak Health Collaborates with Major Northeast Regional Plan to Bridge HEDIS Care Gaps Using Ontrak Quality Solution

Ontrak Health to Report 2024 Third Quarter Financial Results on November 13, 2024

Ontrak Health Expands Behavioral Health Solutions with Sentara Health Plans for Commercial and Marketplace Populations

Ontrak Health Announces 2024 Third Quarter Financial Results

BPTH

LASE

PSRO

American Shared Hospital Services Common Stock

American Shared Hospital

ATI Physical Therapy, Inc. Class A Common Stock

ATI Physical Therapy

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

CareMax

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Kindly MD

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Nutex Health

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Psychemedics

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Syra Health

Vivos Therapeutics

Roth MKM

Canaccord Genuity

RBC Capital

Comments

Ontrak

Vendite allo scoperto

Ontrak (NASDAQ:OTRK) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO